<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193267</url>
  </required_header>
  <id_info>
    <org_study_id>HS23339 (B2019:108)</org_study_id>
    <nct_id>NCT04193267</nct_id>
  </id_info>
  <brief_title>Can Magnetic Brain Stimulation Improve Language Function in Primary Progressive Aphasia</brief_title>
  <official_title>rTMS for the Improvement of Language Functioning in the Logopenic Variant of Primary Progressive Aphasia; a Feasibility and Tolerability Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the feasibility of using repetitive transcranial&#xD;
      magnetic stimulation (rTMS) - a form of non-invasive brain stimulation - to improve language&#xD;
      functioning in individuals who have the logopenic variant of primary progressive aphasia&#xD;
      (PPA-L) - a slowly progressive impairment of language, characterized by difficulties with&#xD;
      word-finding, sentence repetition and sentence comprehension.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label pilot study that aims to recruit 10 individuals with diagnosed&#xD;
      logopenic primary progressive aphasia (PPA-L) to investigate the tolerability and efficacy of&#xD;
      using repetitive transcranial magnetic stimulation (rTMS) to improve language functioning in&#xD;
      this disorder. rTMS is a non-invasive method of brain stimulation that uses rapid magnetic&#xD;
      pulses applied over the scalp to activate neurons in a specified target location of the&#xD;
      brain.&#xD;
&#xD;
      A variety of language tests will be administered to participants prior to rTMS treatment as&#xD;
      well as following 30 sessions of daily rTMS. Additionally, language testing will be performed&#xD;
      during the first session of rTMS treatment in order to assess the effect of simultaneous rTMS&#xD;
      administration on language function. Performance on the pre- and post-treatment tests will be&#xD;
      compared to determine the effect of rTMS treatment on language abilities.&#xD;
&#xD;
      Treatment will consist of daily sessions of high frequency (10 Hz) rTMS applied over the left&#xD;
      temporal gyrus. Patients will receive one session of rTMS per day for 30 consecutive&#xD;
      weekdays. Each session will take approximately 45 minutes to complete.&#xD;
&#xD;
      As a pilot study, this research will be used to evaluate the effect size and the feasibility&#xD;
      of a more definitive project in the future. Both patient response and tolerability to rTMS&#xD;
      will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in score on the Druks and Masterson Naming Task</measure>
    <time_frame>One week pre- and one week post-rTMS treatment</time_frame>
    <description>Assessment of change in language function as a result of rTMS intervention. Minimum score = 0. Maximum score = 24. Higher scores indicate better naming performance.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Logopenic Progressive Aphasia</condition>
  <arm_group>
    <arm_group_label>Repetitive Transcranial Magnetic Stimulation (rTMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 sessions of high-frequency (10Hz) repetitive stimulation applied over the posterior region of the left superior temporal gyrus in patients with logopenic primary progressive aphasia (PPA-L) using a MagStim Rapid2 Transcranial Magnetic Simulation machine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MagStim Rapid2 Transcranial Magnetic Simulation</intervention_name>
    <description>A non-invasive method of brain stimulation</description>
    <arm_group_label>Repetitive Transcranial Magnetic Stimulation (rTMS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PPA-L (confirmed by a neurologist or neuropsychiatrist who has observed&#xD;
             the patient for at least one year);&#xD;
&#xD;
          -  Mild to moderate language impairment as assessed by the Druks and Masterson Naming&#xD;
             Task;&#xD;
&#xD;
          -  Native English speaker.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cerebrovascular disorders, hydrocephalus or intra-cranial mass, documented by MRI;&#xD;
&#xD;
          -  History of traumatic brain injury, seizures, or another neurological disease;&#xD;
&#xD;
          -  Significant medical problems (e.g. poorly controlled diabetes or hypertension or&#xD;
             cancer within the past 5 years);&#xD;
&#xD;
          -  Major depressive disorder, bipolar disorder, schizophrenia, substance use disorder or&#xD;
             mental retardation according to the criteria of the DSM-IV;&#xD;
&#xD;
          -  Any contraindication for rTMS (e.g., implanted metal devices; cardiac pacemaker or&#xD;
             pacemaker wires; neurostimulators; implanted pumps, metal in the body [rods, plates,&#xD;
             screws, shrapnel, dentures, IUD] or metallic particles in the body, surgical clips in&#xD;
             the head, previous neurosurgery, cochlear implants, prosthetic heart valves);&#xD;
&#xD;
          -  Currently pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Tsang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mandana Modirrousta, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjamin Meek</last_name>
    <phone>2042372677</phone>
    <email>rtms@sbgh.mb.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Meek</last_name>
      <phone>2042372677</phone>
      <email>rtms@sbgh.mb.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Progressive Aphasia</keyword>
  <keyword>Brain Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 1, 2021</submitted>
    <returned>October 29, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

